U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced So... (focused integrateddiscovery and developm...)

U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors

Date:10/18/2007

focused, integrated discovery and development companies in Europe. Following a merger between Pfizer and Pharmacia, the rights to Brostallicin were assigned to NMS which continued its development and ultimately licensed worldwide rights to Systems Medicine.

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the context of vulnerability.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Post Your Comments:

U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced So...(focused integrateddiscovery and developm...),Health